Using the Patient’s Own Tumor to Eliminate Neoantigen Prediction & Redesign Clinical Trials
Time: 2:30 pm
day: Conference Day One
Details:
• Deploying a unique mechanism that bypasses complex neoantigen prediction by letting the patient’s own tumor drive antigen presentation, eliminating the need for upfront epitope mapping
• Cutting manufacturing costs and compressing turnaround to just three weeks by growing tumor-derived cells directly to avoid extensive sequencing, synthesis, and custom design
• Targeting patients with minimal residual disease and healthy immune systems to maximize vaccine response, moving beyond late-stage metastatic settings where immune function is severely compromised
• Incorporating adjuvant strategies that strengthen immune activation earlier in the disease course, improving the odds of durable remission
